Tandutinib Not Effective For mRCC
April 26, 2012
A small phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases (FLT3), has concluded that the novel agent has no clinical activity and excessive toxicity, and should not be developed further for mRCC (Shepard et al. Invest New Drugs 2012;30:364-367; www.ncbi.nlm.nih.gov/pubmed/20711630).
Ten patients with mRCC refractory to first-line therapies received tandutinib 500 mg BID. No patient received more than two cycles of therapy. All patients were withdrawn from the study due to disease progression (70%) or toxicity (30%); 60% of subjects required a dose reduction due to adverse events. The most common grade 3 toxicity was fatigue, which occurred in 30%.
The drug has shown anti-leukemic activity in acute myelogenous leukemia in a phase I trial, although generalized muscular weakness and fatigue were dose-limiting toxicities (DeAngelo et al. Blood 2006;108:3674-3681; www.ncbi.nlm.nih.gov/pubmed?term=DeAngelo%202006%203674).
Filed Under: Uncategorized